Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00664170 Completed - Advanced Cancer Clinical Trials

A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

Start date: April 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.

NCT ID: NCT00660920 Completed - Clinical trials for Hematologic Malignancies

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.

NCT ID: NCT00660725 Completed - Clinical trials for Advanced Incurable Solid Malignancy

Study of GemOx and Vandetanib in Advanced Solid Malignancy

Start date: February 2009
Phase: Phase 1
Study type: Interventional

This is a research study that will try to find the highest and safest dose of an experimental drug, vandetanib, that can be given in combination with two standard chemotherapy agents, gemcitabine and oxaliplatin, to subjects with advanced solid malignancies.

NCT ID: NCT00660426 Completed - Solid Tumors Clinical Trials

Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors

Start date: March 2005
Phase: Phase 1
Study type: Interventional

Dose escalation of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.

NCT ID: NCT00658671 Completed - Advanced Cancer Clinical Trials

A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

Start date: April 2008
Phase: Phase 1
Study type: Interventional

A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.

NCT ID: NCT00656461 Completed - Advanced Cancer Clinical Trials

Phase 1 Study of MKC-1 in Patients With Advanced Cancer

Start date: March 2008
Phase: Phase 1
Study type: Interventional

This is an open-label study to determine the highest dose of MKC-1 that may be administered daily on a continuous basis for patients with advanced or refractory solid tumors.

NCT ID: NCT00655655 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Start date: December 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

NCT ID: NCT00654160 Completed - Colorectal Cancer Clinical Trials

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

Start date: June 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with fluorouracil and leucovorin in treating patients with advanced gastrointestinal cancer.

NCT ID: NCT00652054 Completed - Clinical trials for Secondary Malignant Neoplasm of Pancreas

Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in slowing tumor activity in patients with metastatic pancreatic cancer who have previously received 1st line treatment with a gemcitabine regimen. The study is also looking at the safety of S-1.

NCT ID: NCT00651664 Completed - Clinical trials for Advanced Malignancies

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Start date: October 22, 2007
Phase: Phase 1
Study type: Interventional

This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).